BioCryst Pharmaceuticals, Inc. BCRX
Set alert
8.49 USD +0.24 +2.91%
As of Nov 3, 1:11 PM ET
8.19 Day range 8.49
6.23 52-week range 11.22
- YTD
- +8.78%
- 1 year
- +23.69%
- Open
- 8.23
- Prev close
- 8.25
- Mkt cap
- 2.17B
- Vol
- 2.23M
- Avg vol
- 4.61M
- EPS
- -1.40
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.19
- High
- 8.49
- Forward P/E
- 9.99
- Beta
- 0.51
- Short ratio
- 4.97
- Inst. own
- 105.87%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 8.63
- 200-d avg
- 8.75
- 1y target
- 20.55
MAX chart
Events in this range
- Apr 2, 2014Dividend: 0
- Jun 5, 2014Dividend: 0
- Aug 4, 2025Earnings: 0.02; estimate 0.03; surprise -33.33%
- Nov 3, 2025Earnings: 0.06; estimate 0.07; surprise -14.29%
- May 6, 2026Earnings: -2.98; estimate 0.06; surprise -5066.67%
- Jul 7, 2026Rating: RBC Capital · Outperform → Outperform
- Aug 5, 2026Earnings: 0.3; estimate 0.1542; surprise 94.55%
- Aug 6, 2026Rating: Wedbush · Outperform → Outperform
- Aug 6, 2026Rating: RBC Capital · Outperform → Outperform
- Nov 4, 2026Earnings: —; estimate 0.09186; surprise —%
Signals (125)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 2026 | 1 day ago |
| MACD: Sell Signal | Nov 2, 2026 | 1 day ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| SMA: Bullish | Feb 1, 2026 | 9 months ago |
| SMA: Bullish | Feb 1, 2026 | 9 months ago |
| MACD: Buy Signal | Feb 1, 2026 | 9 months ago |
| SMA: Bearish | Jan 1, 2026 | 10 months ago |
| SMA: Bullish | Dec 1, 2025 | 11 months ago |
| SMA: Bearish | Nov 1, 2025 | 1 year ago |
| MACD: Sell Signal | Nov 1, 2025 | 1 year ago |
| SMA: Bearish | Jul 1, 2025 | 1 year ago |
| SMA: Bullish | Apr 1, 2025 | 1 year ago |
| SMA: Bullish | Apr 1, 2025 | 1 year ago |
| SMA: Bearish | Mar 1, 2025 | 1 year ago |
| SMA: Bearish | Mar 1, 2025 | 1 year ago |
| SMA: Bullish | Feb 1, 2025 | 1 year ago |
| SMA: Bearish | Sep 1, 2024 | 2 years ago |
| SMA: Bullish | Aug 1, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 1, 2024 | 2 years ago |
| SMA: Bullish | May 1, 2024 | 2 years ago |
Newest 20 of 125.
Analyst view
Consensus: buy
Buy
Price target (mean) 20.55 +142.1% upside
Now 8.49
- Target (low)
- 11.00
- Target (mean)
- 20.55
- Target (high)
- 32.00
Ratings (0m) 11 9 buy · 2 hold · 0 sell
- Strong buy2
- Buy7
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- This month 11
- 1 month ago 11
- 2 months ago 11
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.115 | 0.10 – 0.13 | 0.16 | -28.1% | 165.68M | +3.9% | 2 |
| Next quarter | 0.13 | 0.11 – 0.15 | 0.2083 | -37.6% | 169.77M | -58.2% | 2 |
| Current year | 0.75 | 0.70 – 0.80 | 0.6347 | +18.2% | 710.08M | -18.8% | 2 |
| Next year | 0.825 | 0.80 – 0.85 | 0.75 | +10.0% | 736.43M | +3.7% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 2026 | JP Morgan | Maintained | Neutral | Neutral |
| Sep 10, 2026 | RBC Capital | Downgrade | Outperform | Sector Perform |
| Sep 8, 2026 | Needham | Reiterated | Buy | Buy |
| Aug 6, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 6, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jul 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jun 30, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jun 30, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| May 7, 2026 | Citizens | Maintained | Market Outperform | Market Outperform |
| May 7, 2026 | Wedbush | Maintained | Outperform | Outperform |
| May 6, 2026 | Needham | Maintained | Buy | Buy |
| Jan 30, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Dec 15, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 5, 2025 | Citizens | Maintained | Market Outperform | Market Outperform |
| Nov 4, 2025 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Nov 4, 2025 | Needham | Maintained | Buy | Buy |
| Oct 15, 2025 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Oct 15, 2025 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Oct 15, 2025 | Needham | Maintained | Buy | Buy |
| Aug 4, 2025 | Needham | Maintained | Buy | Buy |
| Jul 1, 2025 | B of A Securities | Maintained | Buy | Buy |
| Jun 30, 2025 | RBC Capital | Reiterated | Outperform | Outperform |
| Jun 30, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Jun 27, 2025 | Needham | Reiterated | Buy | Buy |
| Jun 25, 2025 | Needham | Reiterated | Buy | Buy |
| May 7, 2025 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| May 6, 2025 | RBC Capital | Reiterated | Outperform | Outperform |
| May 6, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| May 6, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 6, 2025 | Needham | Maintained | Buy | Buy |